File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The prognostic significance of BMP-6 signaling in prostate cancer

TitleThe prognostic significance of BMP-6 signaling in prostate cancer
Authors
KeywordsBMP-6
Metastasis
Noggin
Prostate cancer
Sclerostin
Issue Date2008
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/modpathol/
Citation
Modern Pathology, 2008, v. 21 n. 12, p. 1436-1443 How to Cite?
AbstractThe importance of bone-morphogenetic proteins in prostate cancer is well recognized. Bone-morphogenetic protein-6 overexpression has been shown to increase the aggressiveness and invasiveness of prostate cancer cells. Recent studies on noggin and sclerostin, potent inhibitors of bone-morphogenetic protein signaling, have found that noggin also modifies the ability of prostate cancer cells to metastasize to bone. Taken together, these results suggest that bone-morphogenetic protein-6 signaling is important in prostate cancer progression. Our study investigated the expression of bone-morphogenetic protein-6, noggin and sclerostin in human prostate specimens (n=136) by immunohistochemical staining. We found that bone-morphogenetic protein-6 was increased (P<0.001), whereas sclerostin was decreased (P=0.004) in prostate cancer compared with nodular hyperplasia. In addition, significantly higher level of bone-morphogenetic protein-6 expression was observed in high-grade prostate cancer with Gleason score ≥7 (P=0.027). Bone-morphogenetic protein-6, noggin and sclerostin alone could not predict the development of distant metastasis in our patient cohort. However, high level of bone-morphogenetic protein-6 and low level of noggin, or high level of bone-morphogenetic protein-6 and low level of both noggin and sclerostin expression in primary prostate cancer significantly predicted development of distant metastasis. The predictive value was still valid when only high-grade prostate cancers were included or when patients with secondary lesion other than bone were excluded. Taken together, these results suggest that a high level of bone-morphogenetic protein-6 signaling, resulting from increased expression of bone-morphogenetic protein-6 and decreased expression of its inhibitors, might promote the development of prostate cancer metastases. Our results also imply the potential use of bone-morphogenetic protein-6, noggin and sclerostin expression together as a prognostic predictor for metastatic progression of prostate cancer. © 2008 USCAP, Inc All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/148593
ISSN
2015 Impact Factor: 5.485
2015 SCImago Journal Rankings: 2.803
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, HFen_HK
dc.contributor.authorChan, YPen_HK
dc.contributor.authorCheung, WLen_HK
dc.contributor.authorWong, YCen_HK
dc.contributor.authorWang, Xen_HK
dc.contributor.authorChan, KWen_HK
dc.date.accessioned2012-05-29T06:13:57Z-
dc.date.available2012-05-29T06:13:57Z-
dc.date.issued2008en_HK
dc.identifier.citationModern Pathology, 2008, v. 21 n. 12, p. 1436-1443en_HK
dc.identifier.issn0893-3952en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148593-
dc.description.abstractThe importance of bone-morphogenetic proteins in prostate cancer is well recognized. Bone-morphogenetic protein-6 overexpression has been shown to increase the aggressiveness and invasiveness of prostate cancer cells. Recent studies on noggin and sclerostin, potent inhibitors of bone-morphogenetic protein signaling, have found that noggin also modifies the ability of prostate cancer cells to metastasize to bone. Taken together, these results suggest that bone-morphogenetic protein-6 signaling is important in prostate cancer progression. Our study investigated the expression of bone-morphogenetic protein-6, noggin and sclerostin in human prostate specimens (n=136) by immunohistochemical staining. We found that bone-morphogenetic protein-6 was increased (P<0.001), whereas sclerostin was decreased (P=0.004) in prostate cancer compared with nodular hyperplasia. In addition, significantly higher level of bone-morphogenetic protein-6 expression was observed in high-grade prostate cancer with Gleason score ≥7 (P=0.027). Bone-morphogenetic protein-6, noggin and sclerostin alone could not predict the development of distant metastasis in our patient cohort. However, high level of bone-morphogenetic protein-6 and low level of noggin, or high level of bone-morphogenetic protein-6 and low level of both noggin and sclerostin expression in primary prostate cancer significantly predicted development of distant metastasis. The predictive value was still valid when only high-grade prostate cancers were included or when patients with secondary lesion other than bone were excluded. Taken together, these results suggest that a high level of bone-morphogenetic protein-6 signaling, resulting from increased expression of bone-morphogenetic protein-6 and decreased expression of its inhibitors, might promote the development of prostate cancer metastases. Our results also imply the potential use of bone-morphogenetic protein-6, noggin and sclerostin expression together as a prognostic predictor for metastatic progression of prostate cancer. © 2008 USCAP, Inc All rights reserved.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/modpathol/en_HK
dc.relation.ispartofModern Pathologyen_HK
dc.subjectBMP-6en_HK
dc.subjectMetastasisen_HK
dc.subjectNogginen_HK
dc.subjectProstate canceren_HK
dc.subjectSclerostinen_HK
dc.subject.meshAgeden_US
dc.subject.meshBone Morphogenetic Protein 6 - Biosynthesisen_US
dc.subject.meshBone Morphogenetic Proteins - Biosynthesisen_US
dc.subject.meshCarrier Proteins - Biosynthesisen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshGenetic Markersen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshKaplan-Meier Estimateen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshProstatic Neoplasms - Metabolism - Mortality - Pathologyen_US
dc.subject.meshSignal Transduction - Physiologyen_US
dc.subject.meshTumor Markers, Biological - Analysisen_US
dc.titleThe prognostic significance of BMP-6 signaling in prostate canceren_HK
dc.typeArticleen_HK
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_HK
dc.identifier.emailChan, KW:hrmtckw@hku.hken_HK
dc.identifier.authorityWong, YC=rp00316en_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1038/modpathol.2008.94en_HK
dc.identifier.pmid18931653-
dc.identifier.scopuseid_2-s2.0-56649114367en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-56649114367&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1436en_HK
dc.identifier.epage1443en_HK
dc.identifier.isiWOS:000261109000004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, HF=14018633400en_HK
dc.identifier.scopusauthoridChan, YP=14009821700en_HK
dc.identifier.scopusauthoridCheung, WL=7202742743en_HK
dc.identifier.scopusauthoridWong, YC=7403041798en_HK
dc.identifier.scopusauthoridWang, X=7501854829en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.citeulike3472405-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats